Chemotherapy drug

Phase 3Small molecule

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Chemotherapy drug is one of 393 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

392

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

CholangiocarcinomaPreclinical

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Chemotherapy drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

4 2

Trodelvy

Gilead

Preclinical

37 3

Prolia

Amgen

Preclinical

14 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 6

Zolymbus

AbbVie

Preclinical

1 7

Spravato

WWim Janssens

Preclinical

2 8

Aquasol E

NNational Eye Institute (NEI)

Paracetamol

1 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Small Cell Lung Cancer

NCT05798845

Recruiting

Breast Cancer

NCT07096180

Q3 2027

Phase 2Active, not recruiting

Untreated Advanced NSCLC

NCT05787613

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05315700

Q4 2027

Phase 1/2Recruiting

Advanced Cancers

NCT06840119

Phase 2Not yet recruiting

Advanced Malignant Solid Tumors

NCT06446388

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Unknown status·NNational Taiwan University Hospital·Phase 2·NCT05629429·300 enrolled

Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients

Unknown status·SSohag University·Phase 1·NCT05755581·100 enrolled

Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer

Recruiting·TTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation··NCT07096180·200 enrolled

Show 1 more trial

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06561607·542 enrolled

Non-Small Cell Lung Cancer2 trials

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Recruiting·PPrince of Songkla University··NCT06326086·240 enrolled

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Unknown status·—·Phase 1·NCT05573373·40 enrolled

Chemoradiotherapy1 trial

Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM

Unknown status·EEye & ENT Hospital of Fudan University·Phase 1·NCT05009446·28 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Patients With Advanced Solid Tumors1 trial

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Recruiting·OORIC Pharmaceuticals·Phase 1/2·NCT05315700·350 enrolled

20 more indications

Growth1 trial

Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model

Unknown status·UUniversity Hospital, Linkoeping·Phase 1/2·NCT05289076·40 enrolled

Acute Myeloid Leukemia1 trial

Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT06841952·158 enrolled

Oropharyngeal Cancer1 trial

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Recruiting·—·Phase 2·NCT04900623·145 enrolled

Desmoid Tumor1 trial

Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting

Recruiting·UUniversity Hospital, Strasbourg, France·N/A·NCT06081400·150 enrolled

Multiple Myeloma1 trial

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Recruiting·FFirst Affiliated Hospital of Zhejiang University··NCT06463717·210 enrolled

Cholangiocarcinoma1 trial

RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma

Completed·FFirst People's Hospital of Hangzhou·N/A·NCT05028439·70 enrolled

Advanced Cancers1 trial

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Recruiting·IImmunocore Ltd·Phase 1/2·NCT06840119·600 enrolled

Small Cell Lung Cancer1 trial

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Recruiting·SShanghai Chest Hospital·Phase 2·NCT05798845·124 enrolled

Chemotherapy1 trial

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT04882462·100 enrolled

Ovarian Cancer1 trial

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

Recruiting·NNational Cancer Institute, Naples·Phase 3·NCT05255471·200 enrolled

Gastric Cancer1 trial

Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer

Recruiting·—·Phase 3·NCT04483076·524 enrolled

Endometrial Cancer1 trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06475599·420 enrolled

Advanced or Metastatic Solid Tumor Malignancies1 trial

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Active, not recruiting·AAscendis Pharma Oncology Division A/S·Phase 1/2·NCT05081609·320 enrolled

Untreated Advanced NSCLC1 trial

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Active, not recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 2·NCT05787613·132 enrolled

Pancreatic Cancer1 trial

Carbon Ion RT for Locally Advanced Pancreatic Cancer

Terminated·—·Phase 3·NCT04592861·5 enrolled

Hepatocellular Carcinoma1 trial

RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma

Unknown status·SSun Yat-sen University·N/A·NCT02964260·410 enrolled

Colorectal Cancer1 trial

DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases

Recruiting·TTehran University of Medical Sciences·Phase 3·NCT06555003·116 enrolled

Lung Cancer1 trial

CIETAI and Sequential Radiotherapy in Squamous Lung Cancer

Recruiting·DDong Wang·Phase 2·NCT05892237·50 enrolled

Colon Cancer1 trial

Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars

Recruiting·UUniversity Hospital, Linkoeping·Phase 1/2·NCT06270017·300 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）

Active, not recruiting·HHebei Medical University Fourth Hospital·N/A·NCT06478355·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Chemotherapy drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Chemotherapy drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Breast Cancer4 trials

Non-Small Cell Lung Cancer2 trials

Chemoradiotherapy1 trial

Advanced Malignant Solid Tumors1 trial

Patients With Advanced Solid Tumors1 trial

Growth1 trial

Acute Myeloid Leukemia1 trial

Oropharyngeal Cancer1 trial

Desmoid Tumor1 trial

Multiple Myeloma1 trial

Cholangiocarcinoma1 trial

Advanced Cancers1 trial

Small Cell Lung Cancer1 trial

Chemotherapy1 trial

Ovarian Cancer1 trial

Gastric Cancer1 trial

Endometrial Cancer1 trial

Advanced or Metastatic Solid Tumor Malignancies1 trial

Untreated Advanced NSCLC1 trial

Pancreatic Cancer1 trial

Hepatocellular Carcinoma1 trial

Colorectal Cancer1 trial

Lung Cancer1 trial

Colon Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News